(NORML) The use of cannabis is associated with lower mortality risk in patients with schizophrenia and related psychotic disorders, according to a forthcoming study to be published in the Journal of Psychiatric Research. (Read the abstract of the study online here.)
An international team of investigators from the University of Maryland School of Medicine and Inje University in South Korea assessed the impact of a lifetime history substance use on mortality in 762 subjects with schizophrenia or related disorders.
Researchers reported, “[W]e observed a lower mortality risk-adjusted variable in cannabis-users compared to cannabis non-users despite subjects having similar symptoms and anti-psychotic treatments.”